Highest-materiality recent filing
Medtronic Q4 rev $9.8B (+6.6% organic), non-GAAP EPS $1.55; dividend raised to $0.72
Q4 revenue $9.807B, +9.9% reported / +6.6% organic; GAAP EPS $0.96, non-GAAP EPS $1.55.
Medtronic discloses unauthorized access to corporate IT systems; no patient or product impact found
Unauthorized third party accessed data in certain Medtronic corporate IT systems; incident discovered April 24, 2026.
Medtronic cuts FY2026 EPS guidance on MiniMed charges; FDA clears MiniMed Flex pump
FDA cleared MiniMed Flex insulin pump several months earlier than expected; smartphone-controlled.
GAAP diluted EPS $0.89; non-GAAP diluted EPS $1.36, three cents above Q3 guidance mid-point.
Medtronic Q2 FY26: Revenue $9.0B (+5.5% organic), non-GAAP EPS $1.36 (+8%); raises FY26 guidance
Q2 organic revenue growth 5.5% (beat guidance midpoint by 75 bps); GAAP EPS $1.07 (+8%), non-GAAP EPS $1.36 (+8%).
Medtronic Q1 revenue $8.58B (+4.8% organic); raises FY26 EPS; adds 2 directors, forms new committees
Q1 GAAP EPS $0.81; non-GAAP EPS $1.26 (+2%), revenue $8.58B, organic growth 4.8%.
Medtronic Q4 EPS $1.62 non-GAAP (+11%); to spin off Diabetes; dividend raised to $0.71
Q4 FY25 revenue $8.93B (+5.4% organic); non-GAAP EPS $1.62 (+11% as reported, +16% constant currency).
Medtronic Q3 FY2025 revenue $8.3B, EPS $1.39 non-GAAP beat; organic growth 4.1%
Revenue $8.292B (+2.5% reported, +4.1% organic); GAAP EPS $1.01 (+2%), non-GAAP EPS $1.39 (+7%, above guidance).
Medtronic appoints Thierry Pieton as CFO effective March 3, 2025
Thierry Pieton, former Renault Group CFO, named Medtronic CFO; reports to CEO Geoff Martha.
Medtronic Q2 revenue $8.4B (+5.3%); raises FY25 organic growth and EPS guidance
GAAP diluted EPS $0.99 (up 46% YoY); non-GAAP diluted EPS $1.26 (up 1% as reported, 8% constant currency).
Medtronic Q1 FY25: revenue $7.9B (+2.8%), GAAP EPS $0.80, non-GAAP EPS $1.23; raises FY25 guidance
Revenue $7.915B (adjusted $8.004B), up 5.3% organic; GAAP EPS $0.80, non-GAAP EPS $1.23 (+8% constant currency).
Medtronic CFO Karen Parkhill resigns; interim CFO Gary Corona appointed; FY2025 guidance reaffirmed
Karen Parkhill will resign as EVP & CFO effective Aug 2, 2024, to become CFO of HP Inc.
Medtronic EVP and President of Global Regions Rob ten Hoedt to retire effective June 28, 2024
Rob ten Hoedt, EVP and President of Global Regions, notified retirement on June 1, 2024.
Medtronic reports Q4 FY24 revenue $8.59B, organic growth 5.4%; FY25 EPS guidance $5.40-$5.50
Q4 GAAP diluted EPS $0.49, non-GAAP $1.46; FY24 GAAP diluted EPS $2.76, non-GAAP $5.20.
Medtronic Q3 FY2024: Revenue $8.1B, GAAP EPS $0.99, raises FY24 guidance; exits ventilator business
Q3 revenue $8.089B, up 4.7% reported and 4.6% organic; GAAP EPS $0.99, non-GAAP EPS $1.30.
Medtronic Q2 FY24 revenue up 5.3% to $7.984B; GAAP EPS $0.68, non-GAAP $1.25; raises FY24 guidance
Revenue $7.984B, +5.3% reported / +5.0% organic; GAAP net income $909M ($0.68 EPS) +113%; non-GAAP EPS $1.25.
Medtronic Q1 revenue $7.7B (+6% organic); raises FY24 guidance
Revenue $7.70B, +4.5% reported, +6.0% organic; GAAP EPS $0.59 (-16%), non-GAAP EPS $1.20 (+6%).
Medtronic Q4 revenue beats at $8.5B (+5.6%); raises dividend to $0.69 quarterly
Q4 GAAP EPS $0.88 (-20% YoY); non-GAAP EPS $1.57 (+3%), ahead of expectations.
Medtronic Q3 FY2023 revenue $7.73B (+4.1% organic), non-GAAP EPS $1.30, raises FY guidance
Revenue $7.727B flat as reported, +4.1% organic; GAAP EPS $0.92 (-16%), non-GAAP EPS $1.30 (-4%), both ahead of expectations.
Medtronic Q2 FY2023 revenue down 3%; lowers FY2023 EPS guidance to $5.25-$5.30
Revenue $7.585B, organic growth +2%; GAAP EPS $0.32 (down 67%), non-GAAP EPS $1.30 (down 2%).
Medtronic Q1 FY2023 revenue $7.37B (-4% organic) beats guidance; non-GAAP EPS $1.13 in line
GAAP diluted EPS $0.70 (+25% YoY); non-GAAP diluted EPS $1.13 (-17% YoY), in line with expectations.
Medtronic posts FY22 rev +5%, Q4 adj EPS +2%; hikes dividend 8%, forms kidney JV with DaVita
FY22 revenue $31.686B, +5% reported and organic; Q4 revenue $8.1B, -1% reported, +1% organic.
Medtronic Q3 FY2022 revenue flat at $7.8B; GAAP EPS $1.10 (+17%), non-GAAP EPS $1.37 (+6%)
Revenue $7.763B flat YoY; organic growth 2%; COVID-19 impact on U.S. procedure volumes.
Medtronic Diabetes receives FDA warning letter; lowers Diabetes revenue guidance
FDA warning letter dated Dec 9 for Northridge, CA facility following July 2021 inspection related to MiniMed 600 series pump and controller recalls.
Medtronic amends credit facility extending maturity to Dec 2026 and reducing borrowing costs
Extended credit facility maturity from Dec 12, 2025 to Dec 12, 2026; removed cap on future extensions.
Medtronic Q2 FY2022 revenue $7.85B (+2% organic), non-GAAP EPS $1.32; lowers FY revenue growth view
Revenue $7.847B (+3% reported, +2% organic); GAAP EPS $0.97, non-GAAP EPS $1.32.
Revenue $7.987B, up 23% reported and 19% organic; GAAP EPS $0.56, non-GAAP EPS $1.41.
Brett Wall will be departing from his position as Executive Vice President and President, Neuroscience Portfolio
Dr. Kweli Thompson, currently Senior Vice President and President, Cardiac Rhythm Management, will be assuming the role of Executive Vice President and President, Neuroscience Portfolio, effective June 1, 2026.
On June 18, 2025, the Board of Directors (Board) of Medtronic plc (Company) increased the size of the Board from 10 to 11 and appointed Dr. Joon Lee as a new director of the Company, in each case effective as of June 18, 2025.
Skip Kiil would be assuming the role of EVP and President, Cardiovascular Portfolio
Sean Salmon would be departing from his position as EVP and President, Cardiovascular Portfolio
On March 12, 2025, Jennifer M. Kirk, the Global Controller and Principal Accounting Officer of Medtronic plc (Company), notified the Company of her decision to resign from the Company, effective May 2, 2025, to become the chief executive officer of Exubrion Therapeutics, a privately held company.
The Company has appointed Denise L. Blomquist, currently the Company's Assistant Global Controller, to succeed Ms. Kirk as the Company's Global Controller and Principal Accounting Officer, effective March 17, 2025.
On January 21, 2025, Medtronic plc (Company) announced the appointment of Thierry Pieton, age 54, as the Company’s Executive Vice President and Chief Financial Officer (CFO), effective as of March 3, 2025 (Effective Date).
On June 26, 2024, the Company announced that Gary Corona, currently Senior Vice President, Global Financial Planning and Analysis, has been appointed to serve as interim Chief Financial Officer (Interim CFO) of the Company, effective upon Ms. Parkhill’s departure.
On June 21, 2024, Karen L. Parkhill, Executive Vice President and Chief Financial Officer of Medtronic plc (Company), notified the Company of her decision to resign from the Company, effective August 2, 2024.
On June 1, 2024, Rob ten Hoedt, Executive Vice President and President, Global Regions of Medtronic plc (Company), notified the Company of his decision to retire from the Company, effective as of June 28, 2024.
Mr. White will leave the Company effective April 26, 2024, and because Mr. White’s separation from Medtronic constitutes a termination without cause, Mr. White will receive severance payments and benefits consistent with Medtronic’s severance practices for executive officers, as described in Medtronic’s 2023 Proxy Statement filed with the Securities and Exchange Commission on August 11, 2023.
Max materiality 0.90 · Median 0.65 · Most common event earnings